Efficacy and safety of tocilizumab for polyarticular‐course juvenile idiopathic arthritis in the open‐label two‐year extension of a phase III trial

Patients showed high‐level disease control for the 2 years of the study. Response rates in the 188 patients of this extension for JIA‐ACR50/70/90 were 80.3%/77.1%/59.6%, respectively. The safety profile was consistent with prior studies.

Source:

Arthritis and Musculoskeletal Alliance